Payment overview · 2025
General Payments
12 reported records · 11 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Surgery · CHARLESTON, WV · NPI 1639707458
Verified facts
CMS Open Payments records show Philip Soni Chacko received $1,551.63 in general payments during 2025 across 12 reported records.
Stryker Corporation accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
12 reported records · 11 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $271.93 | 17.5% | 2 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $152.64 | 9.8% | 1 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $151.88 | 9.8% | 1 | 2025 |
| Humacyte Global, Inc. | Unresolved — no canonical attribution shown | $150.00 | 9.7% | 1 | 2025 |
| Getinge USA Sales, LLC | Unresolved — no canonical attribution shown | $146.17 | 9.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$134.08 | 8.6% | 1 | 2025 |
| Thrombolex, Inc. | Unresolved — no canonical attribution shown | $126.82 | 8.2% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $125.00 | 8.1% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $121.68 | 7.8% | 1 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $121.43 | 7.8% | 1 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $50.00 | 3.2% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,501.63 | 11 |
| Education | $50.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $271.93 | 2 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $152.64 | 1 | 2025 |
Source payment records
|
|||||
| TREO ABDOMINAL STENT-GRAFT SYSTEM Normalized: treo abdominal stent graft system |
Device | Bolton Medical Inc | $151.88 | 1 | 2025 |
Source payment records
|
|||||
| Symvess Normalized: symvess |
Biological | Humacyte Global, Inc. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| FLIXENE Normalized: flixene |
Device | Getinge USA Sales, LLC | $146.17 | 1 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $134.08 | 1 | 2025 |
Source payment records
|
|||||
| Bashir Endovascular Catheter Normalized: bashir endovascular catheter |
Device | Thrombolex, Inc. | $126.82 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| PICO 7 Normalized: pico 7 |
Device | Smith+Nephew, Inc. | $121.68 | 1 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $121.43 | 1 | 2025 |
Source payment records
|
|||||
| GORE-TEX Vascular Graft Normalized: gore tex vascular graft |
Device | W. L. Gore & Associates, Inc. | $50.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 27 | 27 |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,551.63 · 12 records | Stryker Corporation | Bashir Endovascular Catheter, ENDURANT IIS, FLIXENE, FLOWTRIEVER, GORE-TEX Vascular Graft, NUZYRA, PICO 7, RotarexS 6 F x 135 cm, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Symvess, TREO ABDOMINAL STENT-GRAFT SYSTEM | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error